Replimune (REPL) Other Non-Current Assets (2018 - 2025)
Replimune's (REPL) quarterly Other Non-Current Assets came in at $1.7 million in Q4 2025, up 42.0% year-on-year from $1.2 million in Q4 2024, and up 42.0% quarter-over-quarter from $1.2 million in Q3 2025.
Replimune (REPL) Other Non-Current Assets (2018 - 2025) Analysis & Trends
Replimune has disclosed Other Non-Current Assets across 8 years of filings, most recently posting $1.7 million for Q4 2025.
- Other Non-Current Assets for Q4 2025 came in at $1.7 million, up 42.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.7 million (up 42.0% YoY), and the FY2025 annual result was $1.2 million, changed N/A from the prior year.
- Other Non-Current Assets came in at $1.7 million for Q4 2025 at Replimune, up from $1.2 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $1.7 million in Q3 2024 to a low of $1.2 million in Q4 2024.
- The 5-year median for Other Non-Current Assets is $1.6 million (2021), against an average of $1.6 million.
- Peak annual rise in Other Non-Current Assets reached 42.0% in 2025, while the deepest fall reached 29.62% in 2025.
- Replimune's Other Non-Current Assets stood at $1.6 million in 2021, then changed by 0.0% to $1.6 million in 2022, then changed by 0.0% to $1.6 million in 2023, then declined by 26.65% to $1.2 million in 2024, then soared by 42.0% to $1.7 million in 2025.
- The last three Other Non-Current Assets figures came in at $1.7 million (Q4 2025), $1.2 million (Q3 2025), and $1.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Replimune | 780.01 Mn | 510.88 Mn | - | 1.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.70 Mn |
| Sep 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 1.20 Mn |
| Mar 31, 2025 | 1.20 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.71 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Dec 31, 2023 | 1.64 Mn |
| Sep 30, 2023 | 1.64 Mn |
| Jun 30, 2023 | 1.64 Mn |
| Mar 31, 2023 | 1.64 Mn |
| Dec 31, 2022 | 1.64 Mn |
| Sep 30, 2022 | 1.64 Mn |
| Jun 30, 2022 | 1.64 Mn |
| Mar 31, 2022 | 1.64 Mn |
| Dec 31, 2021 | 1.64 Mn |
| Sep 30, 2021 | 1.64 Mn |
| Jun 30, 2021 | 1.64 Mn |
| Mar 31, 2021 | 1.64 Mn |
| Dec 31, 2020 | 1.64 Mn |